Article Sidebar
Published:
Nov 5, 2015Keywords:
Article Details
Copyright: Creative Commons Attribution CC.
This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.
Main Article Content
Effect of Qianlie Xiaozheng Tang, a Chinese herbal decoction, on castration resistant prostate cancer: A pilot study
Abstract
Background: To examine the effect of Qianlie Xiaozheng Tang (QLXZT), a Chinese herbal decoction, on treating castration resistant prostate cancer (CRPC).
Materials and Methods: A total of 70 men with CRPC were recruited and randomly allocated into treatment groups (treated with QLXZT and conventional therapy) or control group (treated with conventional therapy) for 12 weeks treatment. Primary endpoint was serum prostate specific antigen (PSA) concentration. Secondary endpoints included patients' quality of life measured by Functional Assessment of Cancer Therapy-Prostate questionnaire, and prostate cancer-specific anxiety assessed by Memorial Anxiety Scale for Prostate Cancer.
Results: After a 12-week treatment, the PSA level in control group rose remarkably from 45.3 ± 17.0 to 76.0 ± 56.7 ng/ml (P=0.0015). By contrast, the PSA level in treatment group did not increase significantly (P>0.05). The scores of Functional Assessment of Cancer Therapy Prostate in each domain changed significantly (P<0.05) in treatment group whereas the scores in control group did not differ from the baseline. In addition, the scores of Memorial Anxiety Scale for Prostate Cancer in treatment group dropped from 30.5 ± 4.7 to 27.0 ± 3.9 (P<0.001) while no significant difference was found between baseline and post-treatment in control group (P>0.05).
Conclusions: QLXZT could slow PSA progression, enhance quality of life and alleviate the prostate cancer-specific anxiety in patients with CRPC.
Keywords: Prostate Cancer; Traditional Chinese Medicine; Quality of Life; cancer-specific anxiety
